The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sunflower Therapeutics Closes $3M Agreement for Future Equity (SAFE) with Oversubscription
Dec 03, 2024•over 1 year ago
Contract Type
agreement
MedfordBiotechnology
Description
Sunflower Therapeutics announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals. This oversubscription provides the necessary runway to support the continued launch of Sunflower’s innovative Daisy Petal™ and Dahlia Petal™ perfusion fermentation systems.
Company Information
Company
Sunflower Therapeutics
Location
200 Boston Ave
Medford, Massachusetts, United States
About
Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.
MedfordBiotechnology